The maximum funding request is $150k over a two year period. Indirect cost recovery or institutional overhead costs are not provided. - February 6, 2026 (Letter of Intent); April 13, 2026 (Application, by invitation only)
Leukemia Research Foundation
This grant supports early-career investigators of exceptional creativity who propose highly innovative research projects with the potential to impact broad, essential areas of leukemia research.
Each five-year award will be for a total of $375,000, received as five annual payments of $75,000. Budgets can be tailored to address the situations of individual recipients. - Thursday, January 29, 2026
Foundation Fighting Blindness (FFB), US
The award’s goal is to help advance junior clinical research scientists in their professional endeavors to cure.
For detailed eligibility notes, please refer to the link above. - Monday, January 19, 2026
Milken Institute
ATF-BSI welcomes proposals to investigate sarcoidosis regardless of organ system. The scientific focus of ATF- BSI proposals should address one or more of the suggested focus areas.
Selected research projects will be supported up to EUR 150k (total). - Thursday, December 15, 2026(LOI)
European Society for Paediatric Endocrinology (ESPE)
IFCAH aims to develop better ways to treat CAH (Congenital Adrenal Hyperplasia), allowing people to live better, healthier lives. Specific goals are available at the link below.
$1.25M over a 5 year period. Institutions will receive up to 10% indirect costs on top of awarded funds. - Thursday, January 15, 2026
Cancer Research Institute
The CRI Lloyd J. Old STAR Program — Scientists TAking Risks — provides long-term, flexible funding to mid-career scientists, giving them the freedom to pursue high-risk, high-reward research at the leading edge of cancer immunotherapy.
Up to $400,000 over 3 years (maximum of $135,000 in any one year). - Monday January 12, 2026 (LOI)
ChadTough Defeat DIPG Foundation
This grant provides three years of funding to a new DIPG/DMG investigator for hypothesis-driven research projects. The investigator may be either a newly independent researcher establishing a new DIPG/DMG research lab, or an established researcher who has not previously conducted brain tumor research.
Up to $600,000 over 3 years (maximum of $200,000 per year). - Monday January 12, 2026 (LOI)
ChadTough Defeat DIPG Foundation
This grant provides three years of funding for hypothesis-driven research projects. The proposed research must represent an innovative approach to a major challenge in DIPG/DMG research.
Up to a total of $900,000 for up to three years. - Wednesday January 07, 2026 (LOI)
Breakthrough T1D, US
This funding opportunity aims to support the development of tolerance induction approaches for islet cell therapy that enables graft-specific immune protection without compromising natural immune defenses.
National Institute of Health
Leukemia Research Foundation
National Psoriasis Foundation (NPF)
Foundation Fighting Blindness (FFB), US
Milken Institute
European Society for Paediatric Endocrinology (ESPE)
Cancer Research Institute
ChadTough Defeat DIPG Foundation
Breakthrough T1D, US
